Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis
Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median between 2 and 4 years which leads to a profound alteration of the quality of life.
- Trial name
- PALIF (NCT03229343)
- Testing
- Supportive care
- Where
- 11 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID, Covid-19
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells
- Conditions
- COVID, Covid-19, Coronavirus, Pneumonia
- Trial name
- NCT04382547
- Testing
- Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 32 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Community-Acquired Bacterial Pneumonia (CABP)
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
- Trial name
- NCT01198626
- Testing
- JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 32 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Interstitial Lung Disease
HR Chest CT Visual Scoring, Spirometry and Health Related Quality of Life in Evaluating Severity of ILD Patients
To establish a simplified approach for assessment of severity of interstitial lung disease by evaluating the relationship between HRCT findings, the clinical severity score,spirometry and quality of life.
- Trial name
- NCT05999838
- Testing
- HRCT chest visual scoring
- Volunteers
- 50 people
- Sponsor
- Assiut University
Pulmonary Fibrosis
Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine the safety and efficacy of pomalidomide over a 12 week duration in the treatment of chronic cough in patients with IPF as measured by a Cough Symptom Diary, Visual Analogue Scale for…
- Trial name
- NCT01135199
- Testing
- pomalidomide (CC-4047
- Where
- United States
- Sponsor
- Stanford University
Lung; Disease, Interstitial, With Fibrosis
Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease
Exertional dyspnea is a major source of crippling distress and is the hallmark symptom of fibrotic interstitial lung disease (ILD).
- Trial name
- Dyspnea_ILD (NCT01781793)
- Testing
- Room air, Hyperoxia
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm
- Trial name
- PICSI-H (NCT04281784)
- Testing
- EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 2,512 people
- Sponsor
- University of Washington
Lung Disease Interstitial Diffuse
Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Diseases and Its Impact on Quality of Life
Interstitial lung diseases cause scarring and stiffness of the lungs, leading to impaired breathing and reduced quality of life. The diaphragm, the main respiratory muscle, may become weakened in these patients.
- Trial name
- NCT07205627
- Testing
- Rehabilitation program
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Hospital Civil de Guadalajara
Idiopathic Pulmonary Fibrosis (IPF)
Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459.
- Trial name
- IPF (NCT07019090)
- Testing
- HSK44459
- Volunteers
- 120 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pulmonary Sarcoidosis
Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study
Sarcoidosis is a heterogeneous multisystem disorder of unknown etiology which often presents with bilateral hilar lymphadenopathy, pulmonary infiltration and ocular and skin lesions.
- Trial name
- NCT01384123
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Meir Medical Center
Systemic Sclerosis
Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival…
- Trial name
- NCT06472362
- Testing
- HRCT biomarkers
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 1,000 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
Interstitial lung disease (ILD) is a restrictive lung disease characterized by impaired lung function, exercise limitation and skeletal muscle dysfunction.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Pulmonary, Geriatric
- Trial name
- NCT04803617
- Testing
- Assessment of pulmonary function and pectoralis muscle strength
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Habibedurdu
Idiopathic Pulmonary Fibrosis
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550…
- Trial name
- NCT06241560
- Testing
- BI 1015550, Pirfenidone
- Where
- 3 sites in United States, Georgia
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Immunologically-induced Lung Disease, Hypersensitivity Pneumonitis
Wind Instruments' Fungal Contamination
On the basis of 2 cases of immunologically-induced lung disease in 2 saxophonists, the investigators supposed that wind reed instruments could be contaminated with molds.
- Trial name
- NCT01487850
- Testing
- blood sample
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib
GSK3915393 is a new medicine which is being developed for a chronic lung disease called Idiopathic Pulmonary Fibrosis (IPF). This is a healthy participant study which has two parts.
- Trial name
- NCT06625489
- Testing
- Nintedanib, GSK3915393
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
PROOF-Registry New and Extended Belgium -Luxembourg
A Prospective Observational Registry to describe the disease course and outcomes of Idiopathic Pulmonary Fibrosis patients in a real-world clinical setting.
- Trial name
- PROOF-NEXT (NCT03732859)
- Where
- 9 sites in Belgium, Luxembourg
- Volunteers
- 575 people
- Sponsor
- Belgian Thoracic Society
Sarcoidosis, Pulmonary
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.
- Trial name
- RISE-UP (NCT05567133)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Idiopathic Lung Fibrosis, Idiopathic Pulmonary Fibrosis
Breath Analysis in Lung Fibrosis
The aim of the study is to answer the question whether a disease specific profile of breath in patients with idiopathic lung fibrosis can be detected by an untargeted metabolomic study using exhaled breath analysis by mass…
- Trial name
- NCT02437448
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
- Trial name
- NCT06388421
- Testing
- Prospective study assessments
- Where
- 71 sites in United States, Puerto Rico
- Volunteers
- 900 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult..
- Trial name
- NCT05657184
- Testing
- REGEND001
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.